Scarica l'app Stockscreener
0.00
100.00%
-15.96
Dopo l'orario di chiusura:
5.43
5.43
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CARA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.96
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$22.12M
Reddito:
$20.97M
Utile/perdita netta:
$-118.51M
Rapporto P/E:
0.00
EPS:
-2.19
Flusso di cassa netto:
$-94.45M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$19.08
Cara Therapeutics Inc Stock (CARA) Company Profile
Nome
Cara Therapeutics Inc
Settore
Industria
Telefono
203-406-3700
Indirizzo
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Confronta CARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CARA
Cara Therapeutics Inc
|
0.00 | 22.12M | 20.97M | -118.51M | -94.45M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Iniziato | Raymond James | Outperform |
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | Piper Sandler | Overweight |
| 2025-05-21 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-06-30 | Downgrade | Janney | Buy → Neutral |
| 2017-06-30 | Reiterato | Laidlaw | Buy |
| 2017-06-30 | Reiterato | Stifel | Buy |
| 2017-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-28 | Reiterato | Laidlaw | Buy |
| 2017-03-10 | Reiterato | Laidlaw | Buy |
| 2016-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-08 | Reiterato | Needham | Buy |
Mostra tutto
Cara Therapeutics Inc Borsa (CARA) Ultime notizie
Tvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% – Here’s Why - Defense World
Tvardi Therapeutics Reports Q2 2025 Financial Results - MSN
Tvardi Posts Q2 Net Income Turnaround - AOL.com
Tvardi Therapeutics Q2 2025: IPF Enrollment Complete, Q4 Data Expected. - AInvest
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update - Business Wire
Cara Therapeutics Inc to Host Earnings Call - ACCESS Newswire
This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Yahoo Finance
This ‘Strong Buy’ Stock Could Be The Next Big Biotech Breakout - Barchart.com
Tvardi Therapeutics (NASDAQ:TVRD) Coverage Initiated at Raymond James Financial - Defense World
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Business Wire
Tvardi Therapeutics director Shaheen Wirk resigns from board - Investing.com Australia
Tvardi Therapeutics director Shaheen Wirk resigns from board By Investing.com - Investing.com Nigeria
Raymond James Initiates Tvardi Therapeutics at Outperform - MarketScreener
Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com Nigeria
Equities Analysts Offer Predictions for TVRD FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest
Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com
Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener
Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener
Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
How To Trade (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK
Cara Therapeutics Inc Azioni (CARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cara Therapeutics Inc Azioni (CARA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
0.96%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):